Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

Plasmapheresis Clinical Trial

Official title:

Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00001349
• Other study ID #: 930057
• Secondary ID: 93-I-0057
• Status: Terminated
• Start date: March 23, 1993
• Est. completion date: November 9, 2021

Study information

• Verified date: November 2021
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will collect blood plasma and white blood cells for laboratory research using a procedure called apheresis. Apheresis is a method of collecting larger quantities of certain blood components than can safely be collected through a simple blood draw. Patients 7 years of age and older with a parasitic infection or condition associated with a parasitic infection (i.e., elevated levels of IgE antibodies or of a type of white cell called eosinophils) who are currently enrolled in a NIH clinical research protocol may be eligible for this study. Relatives of patients and normal healthy volunteers will also be enrolled. Candidates will have a medical history, physical examination and blood tests. Individuals weighing less than 25 kilograms (55 pounds) may not participate. Participants will undergo one of the following two apheresis procedures: - Automated pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through a cell separator machine. The plasma (liquid part of the blood) and white cells are extracted, and the red cells are re-infused into the donor through a needle in the other arm. The procedure takes 1 to 2 hours. - Manual pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through the cell separator machine. The red blood cells are separated from the rest of the blood and returned to the donor through the same needle. Usually only one needle stick is required and the procedure takes from 30 to 45 minutes. This method is used only in individuals who weigh less than 35 kg (77 pounds).

Description:

In order to carry out in vitro research procedures on the plasma or leukocyte components of blood, it is often necessary to obtain larger quantities of plasma and/or leukocytes, than can be safely obtained by simple phlebotomy. These components can be easily and safely obtained using apheresis procedures in the Clinical Center Apheresis Unit. This protocol is specifically designed to conform to the requirements of the Apheresis Unit for donors to have apheresis procedures (>7 years of age and greater than or equal to 25kg). Donors must first be admitted to another approved clinical research protocol of the LPD, NIAID before they may have the apheresis procedures described in this protocol. The investigational nature of the studies in which the samples will be used, as well as the risks and benefits of the donation process will be explained to all donors, and a signed informed consent document will be obtained.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 205
• Est. completion date: November 9, 2021
• Est. primary completion date: November 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years and older

Eligibility

• INCLUSION CRITERIA:
• Enrolled on another LPD protocol.
• Weight greater than or equal to 25 kg
• Willingness to participate

EXCLUSION CRITERIA:

• Age less than 7 years
• Weight less than 25 kg
• Cardiovascular instability
• Hct less than 30
• Inadequate venous access
• PTT or PT greater than 1.5 normal
• Pregnancy
• Women who are actively breastfeeding
• Other condition which the attending physician or Apheresis Unit staff considers a contraindication to the procedure
• For Hetastarch procedure
• Hypertension
• Evidence of fluid retention

Related Conditions & MeSH terms

• Leukopheresis
• Plasmapheresis

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Boyd A, Ribeiro JM, Nutman TB. Human CD117 (cKit)+ innate lymphoid cells have a discrete transcriptional profile at homeostasis and are expanded during filarial infection. PLoS One. 2014 Sep 25;9(9):e108649. doi: 10.1371/journal.pone.0108649. eCollection 2014. — View Citation

Chatterjee S, Clark CE, Lugli E, Roederer M, Nutman TB. Filarial infection modulates the immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T cells. J Immunol. 2015 Mar 15;194(6):2706-14. doi: 10.4049/jimmunol.1402718. Epub 2015 Feb 9. — View Citation

Santiago Hda C, Ribeiro-Gomes FL, Bennuru S, Nutman TB. Helminth infection alters IgE responses to allergens structurally related to parasite proteins. J Immunol. 2015 Jan 1;194(1):93-100. doi: 10.4049/jimmunol.1401638. Epub 2014 Nov 17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To obtain leukocytes,platelets, and plasma from subjects already enrolled on other NIAID/LPD protocols.	Leukocytes, platelets, and plasma will be collected.	Ongoing as this is a method to collect cells from subjects enrolled on other LPD protocols

External Links

•   NIH Clinical Center Detailed Web Page